

Geraldine O'Sullivan Coyne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3793194/publications.pdf>

Version: 2024-02-01

49
papers

1,282
citations

623188

14
h-index

395343

33
g-index

49
all docs

49
docs citations

49
times ranked

2491
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2022, 28, 279-288.	3.2	10
2	PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 165-180.	1.0	15
3	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37.	3.0	17
4	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. <i>Cancer Cell</i> , 2021, 39, 38-53.e7.	7.7	65
5	Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 749-760.	1.9	3
6	Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3834-3844.	3.2	36
7	Advances in the management of alveolar soft part sarcoma. <i>Current Problems in Cancer</i> , 2021, 45, 100775.	1.0	14
8	Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. <i>JCO Precision Oncology</i> , 2021, 5, 133-144.	1.5	22
9	Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy. <i>European Journal of Cancer</i> , 2020, 138, S10.	1.3	1
10	Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 815-827.	1.1	12
11	Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases. <i>JAMA Oncology</i> , 2020, 6, 1967.	3.4	0
12	Intravenous 5-fluoro-2-â€²-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 979-993.	1.1	13
13	Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. <i>Oncotarget</i> , 2020, 11, 3959-3971.	0.8	8
14	Abstract 805: Intra-tumoral pharmacodynamics of selumetinib in serial biopsies from patients with neurofibroma. , 2020, , .		0
15	Abstract 802: Implementation of optimized research biopsy analyses for clinical pharmacodynamic (PD) studies. , 2020, , .		0
16	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511.	1.1	14
17	Cediranib phaseâ€š study in children with metastatic alveolar softâ€špart sarcoma (ASPS). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27987.	0.8	11
18	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94

#	ARTICLE	IF	CITATIONS
19	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
20	Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. , 2019, , .		2
21	Abstract PR07: Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen) Tj ETQq1 1 0.784314 rgBT /Over 2019, , .		2
22	Role of HSP90 Inhibitors in the Treatment of Cancer. Heat Shock Proteins, 2019, , 125-143.	0.2	0
23	Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.. Journal of Clinical Oncology, 2019, 37, 3067-3067.	0.8	8
24	Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib). Cancer Research, 2019, 79, CT099-CT099.	0.4	1
25	Abstract C008: Tolerability and antitumor activity of paclitaxel is improved by the addition of nilotinib in patients with refractory solid tumors. , 2019, , .		0
26	Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of γ -Secretase. Journal of Investigative Dermatology, 2018, 138, 979-981.	0.3	14
27	A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. Oncologist, 2018, 23, 1269-e125.	1.9	13
28	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs, 2017, 77, 113-130.	4.9	44
29	Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Current Problems in Cancer, 2017, 41, 182-193.	1.0	75
30	Use of precision methods to accelerate drug development in oncology. Expert Review of Precision Medicine and Drug Development, 2017, 2, 109-120.	0.4	0
31	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncology, The, 2017, 18, 587-598.	5.1	261
32	MABp1 for the treatment of colorectal cancer. Expert Opinion on Biological Therapy, 2017, 17, 1155-1161.	1.4	14
33	Clinical Activity of the γ -Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive) Tj ETQq1 1 0.784314 rgBT /Over 0.8 145		
34	Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations. , 2017, , .		1
35	Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials. Seminars in Oncology, 2016, 43, 446-452.	0.8	8
36	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs, 2016, 34, 355-363.	1.2	58

#	ARTICLE	IF	CITATIONS
37	Delivering on the promise. <i>Current Opinion in Oncology</i> , 2015, 27, 475-481.	1.1	20
38	Immune play: defending the liver. <i>Hepatic Oncology</i> , 2015, 2, 15-18.	4.2	0
39	Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 97-110.	1.0	7
40	An overview of the NCI precision medicine trials-NCI MATCH and MPACT. <i>Chinese Clinical Oncology</i> , 2015, 4, 31.	0.4	53
41	Abstract 1316: Evaluation of immune cell subsets of cancer patients treated with a fully human IgG1 anti-PD-L1 MAb (MSB0010718C) capable of mediating ADCC of human tumor cells. <i>Cancer Research</i> , 2015, 75, 1316-1316.	0.4	1
42	Adding fuel to the fire: Immunogenic intensification. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3306-3312.	1.4	4
43	Clinical experience with ramucirumab: outcomes in breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1351-1360.	1.4	5
44	Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations. <i>Journal of Clinical Oncology</i> , 2014, 32, 986-988.	0.8	50
45	Our experts highlight the most important research articles across the spectrum of topics relevant to the field of hepatic oncology. <i>Hepatic Oncology</i> , 2014, 1, 359-360.	4.2	0
46	Abstract 5012: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates. , 2014, , .		0
47	Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 643-650.	1.0	6
48	Curcumin induces apoptosis-independent death in oesophageal cancer cells. <i>British Journal of Cancer</i> , 2009, 101, 1585-1595.	2.9	137
49	Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E2-independent mechanisms. <i>Cancer Letters</i> , 2007, 256, 246-258.	3.2	18